NANOKINE

NANOKINE

NANOKINE

NANOKINE

NANOKINE

NANOKINE

NANOKINE

Description

NANOKINE is produced from raw high purity materials erythropoietin (EPO). Material EPO is produced by recombinant DNA techniques on ovarian cell lines marsupial cheeks of China (Chinese Hamster ovary, CHO). EPO gene coding for the protein was transferred into CHO cells (no gene EPO). CHO cell lines were cultured EPO gene in specific environments to produce EPO.
Erythropoietin alfa is recombinant human erythropoietin, contains 165 amino acids. Recombinant human erythropoietin and erythropoietin (rHu EPO) completely natural sequence similarity and amino acid sequences oligosaccharide is very similar in structure carbon hydrate. Molecular group is more glycosylated. Erythropoietin has biological effects and immunology as endogenous erythropoietin and activity of 100,000 IU to 1 mg hormone.
NANOKINE is supplied in sterile, white, lyophilized powder. The reconstituted preparation with 1 ml solvent (containing 0.9% benzyl alcohol) results in a clear, colorless solution.
NANOKINE is supplied as an injectable solution in vials and prefilled syringes.  Injectable solution is sterile, clear, and colorless.
Administration route: SC or IV injection.

INDICATIONS
- Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:
• Treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis
• Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.
- Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).
CONTRAINDICATIONS
NANOKINE should NOT be used for patients:
Have uncontrolled hypertension.
Develop pure red cell aplasia (PRCA) following treatment with erythropoietin
Hypersensitivity to the active substance or to any of the excipients.
Have surgery and cannot receive adequate antithrombotic prophylaxis for any reason.
Have autologous blood predonation programmes
Are scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation
Suffer severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.
STORAGE, SHELF-LIFE AND PACKING UNITS
Storage: at 2°C - 8°C. Do not freeze. Protect from light.
Shelf life: 24 months from manufacturing date. Reconstituted solution is stable for 7 days at temperatures of 2°C - 8°C.
Packing units:
Box of 1 vial of lyophilized powder NANOKINE 2000 IU, 4000 IU, 10000 IU and 1 vial solvent (1 mL)
Box of 1,10  vial(s) of solution for injection NANOKINE  2000 IU, 4000 IU, 10000 IU  (1 mL)
Box of 01, 06, 12 prefilled syringe(s) of solution for injection NANOKINE 2000 IU, 4000 IU, 10000 IU

 

Related products

Current product

PEGCYTE

Current product

FICOCYTE

Current product

PEGNANO

Current product

FERONSURE